Isolation of non-cytotoxic crotepoxide from the root bark of Croton macrostachyus and the reassignment of its structure

Crotepoxide was isolated for the first time from the root bark of Croton macrostachyus along with other known compounds. This compound along with other compounds was investigated for cytotoxicity and found to be not active against the human cervix carcinoma KB-3-1 cells in micromolar ranges. In addition, the 13C NMR of crotepoxide is reassigned. The structures of the compounds in general were elucidated on the basis of extensive spectroscopic (1D and 2D) studies and literature data.               KEY WORDS: Croton macrostachyus, Crotepoxide, Structure revision, Root bark, Cytotoxicity Bull. Chem. Soc. Ethiop. 2017, 31(3), 465-469.DOI: http://dx.doi.org/10.4314/bcse.v31i3.1

Cytotoxic flavonoids from Erythrina caffra Thunb

Erythrina caffra is an important medicinal plant native to South Africa. Its stem bark was investigated for the flavonoid constituents and biological activity. Some isolated flavonoids, 3, 5, 6, 8, 9, 10, 11, 12,  13, 15 and  16  were found to be active against the human cervix carcinoma KB-3-1 cells with IC50 values in the micromolar range. Compounds 8, 9, 11, 13 and 15 also showed weak to moderate antibacterial activity against some organisms using the disc diffusion assay at loadings of 62.5 μg/disc (8, 11) and 125 μg/disc (9, 13, 15). KEY WORDS: Erythrina caffra, Cytotoxicity, Antibacterial, Flavonoids, Fabaceae Bull. Chem. Soc. Ethiop. 2016, 30(3), 427-435DOI: http://dx.doi.org/10.4314/bcse.v30i3.1

Gene expression profiles of 4‐hydroxy‐N‐desmethyl‐tamoxifen (endoxifen)‐ and 4‐hydroxy‐tamoxifen (4OHTAM)‐treated human breast cancer cells determined by CDNA microarray analysis

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/109798/1/cptclpt2004192.pd

Tamoxifen therapy reduced platelet counts without change in platelet function

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/109840/1/cptclpt2005247.pd

Menopausal status and estrogen receptor genotypes influenced the severity of hot flashes after tamoxifen treatment

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/109844/1/cptclpt200521.pd

Pii‐18

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/110052/1/cptclpt2006156.pd

Estrogen Receptor Genotypes, Menopausal Status, and the Lipid Effects of Tamoxifen

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/109885/1/cpt6100343.pd

Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial

Licensed under a Creative Commons Attribution Non-Commercial Share Alike Licens

Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/109858/1/cptclpt2011174.pd

The Safety, Effectiveness and Concentrations of Adjusted Lopinavir/Ritonavir in HIV-Infected Adults on Rifampicin-Based Antitubercular Therapy

Rifampicin co-administration dramatically reduces plasma lopinavir concentrations. Studies in healthy volunteers and HIV-infected patients showed that doubling the dose of lopinavir/ritonavir (LPV/r) or adding additional ritonavir offsets this interaction. However, high rates of hepatotoxicity were observed in healthy volunteers. We evaluated the safety, effectiveness and pre-dose concentrations of adjusted doses of LPV/r in HIV infected adults treated with rifampicin-based tuberculosis treatment.Adult patients on a LPV/r-based antiretroviral regimen and rifampicin-based tuberculosis therapy were enrolled. Doubled doses of LPV/r or an additional 300 mg of ritonavir were used to overcome the inducing effect of rifampicin. Steady-state lopinavir pre-dose concentrations were evaluated every second month.18 patients were enrolled with a total of 79 patient months of observation. 11/18 patients were followed up until tuberculosis treatment completion. During tuberculosis treatment, the median (IQR) pre-dose lopinavir concentration was 6.8 (1.1-9.2) mg/L and 36/47 (77%) were above the recommended trough concentration of 1 mg/L. Treatment was generally well tolerated with no grade 3 or 4 toxicity: 8 patients developed grade 1 or 2 transaminase elevation, 1 patient defaulted additional ritonavir due to nausea and 1 patient developed diarrhea requiring dose reduction. Viral loads after tuberculosis treatment were available for 11 patients and 10 were undetectable.Once established on treatment, adjusted doses of LPV/r co-administered with rifampicin-based tuberculosis treatment were tolerated and LPV pre-dose concentrations were adequate